Bloomberg News

Dendreon Jumps as More Doctors Prescribe Cancer Therapy

November 02, 2012

Dendreon Jumps as More Doctors Turn to Provenge

The Dendreon Corp. headquarters stands in Seattle, Washington. Photographer: Kevin P. Casey/Bloomberg

Dendreon Corp. (DNDN:US) rose the most in nine months after announcing a third-quarter loss that was less than analysts’ estimates and saying more doctors are using its prostate cancer drug Provenge.

The biotechnology company jumped 16 percent to $4.47 at the close in New York, its biggest single-day advance since Feb. 6. The Seattle-based drugmaker had a loss of 33 cents a share, excluding a restructuring charge. Analysts had expected a loss of 82 cents, according to the average of 22 estimates compiled by Bloomberg.

Urologists prescribing Provenge grew 14 percent in the quarter, Dendreon said today in a statement. The number of oncologists doing so fell by less than 1 percent, an improvement from an 8 percent slide in the second quarter. The medicine accounted for two-thirds of Dendreon’s sales last year and faces competition from new drugs from Johnson & Johnson (JNJ:US) and Medivation Inc. (MDVN:US)

“We delivered strong growth in urology and have continued to improve results in oncology,” Chief Executive Officer John H. Johnson said in a statement today.

The quarter’s net loss of $154.9 million, or $1.04 a share, compared with a net loss of $147.1 million, or $1, a year earlier, Dendreon said.

To contact the reporter on this story: Alex Nussbaum in New York at anussbaum1@bloomberg.net

To contact the editor responsible for this story: Reg Gale at rgale5@bloomberg.net


Burger King's Young Buns
LIMITED-TIME OFFER SUBSCRIBE NOW

(enter your email)
(enter up to 5 email addresses, separated by commas)

Max 250 characters

Companies Mentioned

  • DNDN
    (Dendreon Corp)
    • $2.14 USD
    • -0.05
    • -2.34%
  • JNJ
    (Johnson & Johnson)
    • $102.11 USD
    • -0.09
    • -0.09%
Market data is delayed at least 15 minutes.
 
blog comments powered by Disqus